Skip to main content

Aprea Therapeutics, Inc.

corporate_fare Company Profile

Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed APRE - Latest Insights

APRE
Apr 22, 2026, 5:01 PM EDT
Filing Type: S-3
Importance Score:
9
APRE
Apr 20, 2026, 6:30 AM EDT
Filing Type: PRE 14A
Importance Score:
8
APRE
Apr 01, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
7
APRE
Apr 01, 2026, 4:15 PM EDT
Filing Type: 4
Importance Score:
9
APRE
Mar 30, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
10
APRE
Mar 30, 2026, 8:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
APRE
Mar 19, 2026, 5:16 PM EDT
Filing Type: 424B3
Importance Score:
9
APRE
Mar 16, 2026, 8:30 AM EDT
Filing Type: 10-K
Importance Score:
8
APRE
Mar 16, 2026, 8:15 AM EDT
Filing Type: 8-K
Importance Score:
8
APRE
Feb 20, 2026, 6:02 AM EST
Filing Type: S-3
Importance Score:
8
APRE
Feb 18, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
APRE
Feb 02, 2026, 4:08 PM EST
Filing Type: 4
Importance Score:
7
APRE
Jan 29, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
9
APRE
Jan 23, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
9
APRE
Jan 09, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7